T1	PrimaryOutcome 70 119	progress to severe disease (PaO2/FiO2 ratio <100)
T2	TimeFrame 120 156	any time within 28 days of enrolment
T3	PrimaryOutcome 160 179	all-cause mortality
T4	TimeFrame 180 190	at 28 days
T5	SecondaryOutcome 386 429	clinical improvement and symptom resolution
T6	TimeFrame 430 438	on day 7
R1	MeasuredAt Arg1:T5 Arg2:T6	
T7	SecondaryOutcome 440 488	variation in fraction of inspired oxygen (Fio2%)
T8	TimeFrame 489 514	on days 1, 3, 5, 7 and 14
R2	MeasuredAt Arg1:T7 Arg2:T8	
T9	SecondaryOutcome 516 673	total duration of respiratory support during hospitalization and post enrolment duration of respiratory support till day 28 or discharge whichever is earlier
T10	SecondaryOutcome 675 718	negative conversion of SARS-CoV-2 viral RNA
T12	TimeFrame 719 734	on days 3 and 7
R3	MeasuredAt Arg1:T10 Arg2:T12	
T13	SecondaryOutcome 736 756	levels of biomarkers
T14	TimeFrame 757 808	on days 3 and 7 post enrolment compared to baseline
R4	MeasuredAt Arg1:T13 Arg2:T14	
T15	SecondaryOutcome 810 844	requirement of vasopressor support
T16	SecondaryOutcome 850 891	clinical improvement on WHO ordinal scale
T17	TimeFrame 892 923	on day 0,1,3,5,7,14 and 28 days
R5	MeasuredAt Arg1:T16 Arg2:T17	
T18	OtherOutcome 1133 1246	frequency of minor and serious adverse event (death and invasive mechanical ventilation, hemodynamic instability)
T19	TimeFrame 1247 1279	within 6 hours of CP transfusion
R6	MeasuredAt Arg1:T18 Arg2:T19	
T20	OtherOutcome 1298 1319	serious adverse event
R7	MeasuredAt Arg1:T1 Arg2:T2	
R8	MeasuredAt Arg1:T3 Arg2:T4	
